China Sinopharm and Kexing COVID-19 vaccines entered the ＂COVID-19 Vaccine Implementation Plan＂ vaccine library.

Xinhua News Agency, Geneva, July 12 (Reporter Chen Junxia and Nie Xiaoyang) GAVI)12 released a press release on July 12, announcing that it had signed pre-purchase agreements with China Sinopharm Group and Kexing Company respectively, which means that Sinopharm and Kexing vaccines have entered the "COVID-19 Vaccine Implementation Plan" (COVAX) vaccine bank and can be supplied to COVAX for COVID-19 epidemic prevention and control in developing countries from July.

COVAX is dominated by the World Health Organization and the Global Alliance for Vaccine Immunization. According to the press release, considering that these two vaccines have entered the WHO emergency use list, they can be supplied to COVAX participants immediately. According to the agreement, two China companies can supply COVAX with 110 million doses of COVID-19 vaccine before the end of October this year, and then supply it for a long time.

The agreement between GAVI and China comes at a time when the world, especially developing countries, urgently need to expand vaccination coverage and curb the spread of Covid-19. Seth Berkeley, CEO of GAVI, said in the communique: "I welcome today’s agreement, which enables COVAX participants to get vaccines immediately."

The relevant personnel of the Permanent Mission of China to the United Nations said that the signing of the agreement between the two companies and the Global Alliance for Vaccine Immunization is an important manifestation of China’s commitment to implement vaccine as a "global public product" with practical actions. China government has been actively encouraging and supporting China vaccine research and development enterprises to participate in COVAX and provide vaccines to developing countries. At present, a number of COVID-19 vaccines in China have obtained emergency use licenses in China, and a number of vaccines are in the clinical trial stage. In addition, many China vaccine companies have expressed their positive intention to join COVAX. We expect more China vaccines to enter the WHO emergency use list as soon as possible and be selected into COVAX vaccine bank as soon as possible, thus making positive contributions to global solidarity against the epidemic.